Cited by 1,107Nanoparticle-Based Drug DeliveryBarrier Structure and Function StudiesDrug Transport and Resistance Mechanisms

The DOI matches its Crossref record; 47 of the 50 references it cites were found in a registry or an index.

Nanoparticulate systems for brain delivery of drugs.

Kreuter, Jörg·2001·Advanced Drug Delivery Reviews

DOI 10.1016/s0169-409x(00)00122-8

Open this paper in CoChat — free account

Abstract

The blood--brain barrier (BBB) represents an insurmountable obstacle for a large number of drugs, including antibiotics, antineoplastic agents, and a variety of central nervous system (CNS)-active drugs, especially neuropeptides. One of the possibilities to overcome this barrier is a drug delivery to the brain using nanoparticles. Drugs that have successfully been transported into the brain using this carrier include the hexapeptide dalargin, the dipeptide kytorphin, loperamide, tubocurarine, the NMDA receptor antagonist MRZ 2/576, and doxorubicin. The nanoparticles may be especially helpful for the treatment of the disseminated and very aggressive brain tumors. Intravenously injected doxorubicin-loaded polysorbate 80-coated nanoparticles were able to lead to a 40% cure in rats with intracranially transplanted glioblastomas 101/8. The mechanism of the nanoparticle-mediated transport of the drugs across the blood-brain barrier at present is not fully elucidated. The most likely mechanism is endocytosis by the endothelial cells lining the brain blood capillaries. Nanoparticle-mediated drug transport to the brain depends on the overcoating of the particles with polysorbates, especially polysorbate 80. Overcoating with these materials seems to lead to the adsorption of apolipoprotein E from blood plasma onto the nanoparticle surface. The particles then seem to mimic low density lipoprotein (LDL) particles and could interact with the LDL receptor leading to their uptake by the endothelial cells. After this the drug may be released in these cells and diffuse into the brain interior or the particles may be transcytosed. Other processes such as tight junction modulation or P-glycoprotein (Pgp) inhibition also may occur. Moreover, these mechanisms may run in parallel or may be cooperative thus enabling a drug delivery to the brain.

Integrity signals

Registry

Crossref · 10.1016/s0169-409x(00)00122-8

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.
Cordon‐Cardo, C., O’Brien, J. P., Casals, D., Rittmann-Grauer, L., Biedler, J. L., Melamed, M. R., & Bertino, J. R. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.2.695 · Cited by 1,750
Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins
Pitas, R. E., Boyles, J. K., Lee, S. H., Foss, D., & Mahley, R. W. (1987) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(87)90295-5 · Cited by 693
Brain drug delivery of small molecules using immunoliposomes
Huwyler, J., Wu, D., & Pardridge, W. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14164 · Cited by 660
An Easier, Reproducible, and Mass‐Production Method to Study the Blood–Brain Barrier In Vitro
Dehouck, M., Méresse, S., Delorme, P., Fruchart, J., & Cecchelli, R. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb01236.x · Cited by 548
Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles)
Kreuter, J., Alyautdin, R. N., Kharkevich, D. A., & Aa, I. (1995) · Brain Research · doi:10.1016/0006-8993(95)00023-j · Cited by 538
Significant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles
Gulyaev, A. E., Gelperina, S. E., Skidan, I. N., Antropov, A. S., Kivman, G. Y., & Kreuter, J. (1999) · Pharmaceutical Research · doi:10.1023/a:1018983904537 · Cited by 521
A New Function for the LDL Receptor: Transcytosis of LDL across the Blood–Brain Barrier
Dehouck, B., Fenart, L., Dehouck, M.-P., Pierce, A., Torpier, G., & Cecchelli, R. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.138.4.877 · Cited by 490
Hyperalgesia Induced by Naloxone Follows Diurnal Rhythm in Responsivity to Painful Stimuli
Frederickson, R. C. A., Burgis, V., & Edwards, J. D. (1977) · Science · doi:10.1126/science.561998 · Cited by 379
Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo.
Pardridge, W. M., Buciak, J. L., & Friden, P. M. (1991) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20567-5 · Cited by 358
Delivery of Loperamide Across the Blood-Brain Barrier with Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles
Alyautdin, R. N., Petrov, V. E., Langer, K., Berthold, A., Kharkevich, D. A., & Kreuter, J. (1997) · Pharmaceutical Research · doi:10.1023/a:1012098005098 · Cited by 352
Pharmacokinetics and distribution of a biodegradable drug-carrier
Grislain, L., Couvreur, P., Lenaerts, V., Roland, M., Campeneere, D. D.-D., & Speiser, P. P. (1983) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(83)90166-7 · Cited by 305
The Blood-brain Barrier: Principles for Targeting Peptides and Drugs to the Central Nervous System
Begley, D. J. (1996) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1996.tb07112.x · Cited by 291
The Use of Surfactants to Enhance the Permeability of Peptides Through Caco-2 Cells by Inhibition of an Apically Polarized Efflux System
Nerurkar, M. M., Burton, P. S., & Borchardt, R. T. (1996) · Pharmaceutical Research · doi:10.1023/a:1016033702220 · Cited by 287
Drug Transfer Across the Blood‐Brain Barrier: Correlation Between In Vitro and In Vivo Models
Dehouck, M., Jolliet, P., Brée, F., Fruchart, J., Cecchelli, R., & Tillement, J. P. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb10055.x · Cited by 286
Nanoparticle Technology for Delivery of Drugs Across the Blood–Brain Barrier
Schröeder, U., Sommerfeld, P., Ulrich, S., & Sabel, B. A. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js980084y · Cited by 275
The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a blockcopolymer - poloxamine 908
Illum, L., Davis, S. S., Müller, R. H., Mak, E., & West, P. (1987) · Life Sciences · doi:10.1016/0024-3205(87)90138-x · Cited by 273
Upregulation of the low density lipoprotein receptor at the blood-brain barrier: intercommunications between brain capillary endothelial cells and astrocytes.
Dehouck, B., Dehouck, M. P., Fruchart, J. C., & Cecchelli, R. (1994) · The Journal of cell biology · doi:10.1083/jcb.126.2.465 · Cited by 240
Reversal of multidrug resistance by surfactants
Woodcock, D., Linsenmeyer, M. E., Chojnowski, G. M., Kriegler, A., Nink, V., Webster, L., & Sawyer, W. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.217 · Cited by 233
Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80–coated polybutylcyanoacrylate nanoparticles: Anin situbrain perfusion study
Alyautdin, R. N., Tezikov, E. B., Ramge, P., Kharkevich, D. A., Begley, D. J., & Kreuter, J. (1998) · Journal of Microencapsulation · doi:10.3109/02652049809006836 · Cited by 229
Toxicity of Polyalkylcyanoacrylate Nanoparticles II: Doxorubicin-Loaded Nanoparticles
Couvreur, P., Kante, B., Grislain, L., Roland, M., & Speiser, P. P. (1982) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600710717 · Cited by 217
Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity
Olivier, J.-C., Fenart, L., Chauvet, R., Pariat, C., Cecchelli, R., & Couet, W. (1999) · Pharmaceutical Research · doi:10.1023/a:1018947208597 · Cited by 213
Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood–brain barrier using surfactant-coated nanoparticles
Kreuter, J., Petrov, V. E., Kharkevich, D. A., & Alyautdin, R. N. (1997) · Journal of Controlled Release · doi:10.1016/s0168-3659(97)00061-8 · Cited by 196
Interaction of Poly(butylcyanoacrylate) Nanoparticles with the Blood-Brain Barrierin vivoandin vitro
Alyaudtin, R. N., Reichel, A., Löbenberg, R., Ramge, P., Kreuter, J., & Begley, D. J. (2001) · Journal of drug targeting · doi:10.3109/10611860108997929 · Cited by 166
Modification of the body distribution of poly(methyl methacrylate) nanoparticles in rats by coating with surfactants
Tröster, S. D., Müller, U., & Kreuter, J. (1990) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(90)90047-8 · Cited by 163
Structural and Functional Variations in Capillary Systems within the Braina
Fenstermacher, J. D., Gross, P. M., Sposito, N. M., Acuff, V., Pettersen, S. E., & Gruber, K. (1988) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1988.tb51416.x · Cited by 162
Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles
Kattan, J. G., Droz, J., Couvreur, P., Marino, J. P., Boutan-Laroze, A., Rougier, P. R., Brault, P., Vranckx, H., Grognet, J., Morge, X., et al. (1992) · Investigational New Drugs · doi:10.1007/bf00877245 · Cited by 153
Regional Brain Blood Flow, Blood Volume, and Haematocrit Values in the Adult Rat
Cremer, J. E., & Seville, M. P. (1983) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1983.35 · Cited by 145
Low‐Density Lipoprotein Receptor on Endothelium of Brain Capillaries
Méresse, S., Delbart, C., Fruchart, J., & Cecchelli, R. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb07340.x · Cited by 143
Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections
Schröder, U., & Sabel, B. A. (1996) · Brain Research · doi:10.1016/0006-8993(95)01375-x · Cited by 141
Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system
Friese, A. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(99)00073-9 · Cited by 139
Effect of the Nonionic Surfactant Poloxamer 338 on the Fate and Deposition of Polystyrene Microspheres Following Intravenous Administration
Illum, L., & Davis, S. S. (1983) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600720933 · Cited by 117
Efficacy of Oral Dalargin-loaded Nanoparticle Delivery across the Blood–Brain Barrier
Schröeder, U., Sommerfeld, P., & Sabel, B. A. (1998) · Peptides · doi:10.1016/s0196-9781(97)00474-9 · Cited by 106
Uptake of surfactant-coated poly(methyl methacrylate)-nanoparticles by bovine brain microvessel endothelial cell monolayers
Borchard, G., Audus, K. L., Shi, F., & Kreuter, J. (1994) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(94)90372-7 · Cited by 105
Brain distribution spaces of mannitol-3H, inulin-14C, and dextran-14C in the rat
Wb, S., & Oldendorf, W. (1971) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1971.221.1.214 · Cited by 82
Enhanced Brain Tumor Selectivity of Cationic Magnetic Polysaccharide Microspheres
Pulfer, S. K., & Gallo, J. M. (1998) · Journal of drug targeting · doi:10.3109/10611869808997896 · Cited by 70
Body distribution of 3HH-labelled dalargin bound to poly(butyl cyanoacrylate) nanoparticles after I.V. injections to mice
Schröeder, U., Schröeder, H., & Sabel, B. A. (2000) · Life Sciences · doi:10.1016/s0024-3205(99)00619-0 · Cited by 66
Modulation of Blood-Brain Barrier Permeability
Rapoport, S. I. (1996) · Journal of drug targeting · doi:10.3109/10611869609015962 · Cited by 54
Ultrastructure of Brain Endothelium
Brightman, M. (1992) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-76894-1_1 · Cited by 45
Targeted delivery of DNA by liposomes and polymers
Zhou, X., & Huang, L. (1992) · Journal of Controlled Release · doi:10.1016/0168-3659(92)90082-3 · Cited by 41
Expression of receptors for native and chemically modified low‐density lipoproteins in brain microvessels
Lucarelli, M., Gennarelli, M., Cardelli, P., Novelli, G., Scarpa, S., Dallapiccola, B., & Ström, R. (1997) · FEBS Letters · doi:10.1016/s0014-5793(96)01435-4 · Cited by 39
Spinal subarachnoid perfusion of rhesus monkeys
Kessler, J., Fenstermacher, J. D., & Owens, E. (1976) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1976.230.3.614 · Cited by 38
Genetic differences in daily rhythms of pain sensivity in mice
Castellano, C., Puglisi‐Allegra, S., Renzi, P., & Oliverio, A. (1985) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(85)90135-2 · Cited by 36
Characterization of the Scavenger Receptor on Bovine Cerebral Endothelial Cells In Vitro
de Vries, H. E., Kuiper, J., Boer, A. G. D., van Berkel, T. J. C., & Breimer, D. D. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb09821.x · Cited by 30
Biodistribution of calcitonin encapsulated in liposomes in mice with particular reference to the central nervous system
Chen, D., & Lee, K. H. (1993) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(93)90021-y · Cited by 30
Drug Entry Into the Brain and Its Pharmacologic Manipulation
Greig, N. H. (1992) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-76894-1_20 · Cited by 29
Circadian Phase-Dependent Antinociceptive Reaction in Mice Determined by the Hot-Plate test and the Tail-Flick Test After Intravenous Injection of Dalargin-Loaded Nanoparticles
Ramge, P., Kreuter, J., & Lemmer, B. (1999) · Chronobiology International · doi:10.3109/07420529909016944 · Cited by 27
Do Ultra-Low Frequency ULF) Magnetic Fields Affect the Blood-Brain Barrier?
Begley, D. J., & Kreuter, J. (1999) · Springer eBooks · doi:10.1007/978-1-4615-5051-8_49 · Cited by 6

Research works printed but not linked: 6

Kreuter, 1994, Nanoparticles, Vol. 10, 165
Alyautdin, 1995, Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles, Eur. J. Pharm. Biopharm., 41, 44
Ramge, 2000, Polysorbate 80-coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human, bovine and murine primary brain capilary endothelial cells, Eur. J. Neuro., 12, 1935
Steiniger, 1999, The influence of polysorbate 80-coated nanoparticles on bovine brain capillary endothelial cells in vitro, Proc. Int. Symp. Control. Rel. Bioact. Mater., 26, 789
Fenart, 1999, Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood–brain barrier, J. Pharmacol. Exp. Ther., 291, 1017
Cecchelli, 1997, Receptor-mediated transcytosis of blood-borne molecules through blood–brain barrier endothelial cells: Drug targeting by endogenous transport routes, Proc. Intl. Symp. Control. Rel. Bioact. Mater., 24, 221

Sorted by citations

Nanotoxicology: An Emerging Discipline Evolving from Studies of Ultrafine Particles
Oberdörster, G., Oberdörster, E., & Oberdörster, J. (2005) · Environmental Health Perspectives · doi:10.1289/ehp.7339 · Cited by 7,891
Drug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552
Drug delivery and nanoparticles: Applications and hazards
de Jong (2008) · International Journal of Nanomedicine · doi:10.2147/ijn.s596 · Cited by 3,854
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Nanoparticles in cancer therapy and diagnosis
Brigger, I., Dubernet, C., & Couvreur, P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00044-3 · Cited by 3,040

See all 1,107

Authors: Kreuter, J.
Affiliations: Goethe University Frankfurt (DE)
Corresponding author: Kreuter, Jörg
Venue: Advanced Drug Delivery Reviews
Publisher: Elsevier BV
Published: 2001-03
Volume: 47
Issue: 1
Pages: 65-81
ISSN: 0169-409X (ISSN-L)
DOI: 10.1016/s0169-409x(00)00122-8
OpenAlex: W2072229818
Cited by: 1,107
References: 50
Citations by year: 2026: 15 · 2025: 20 · 2024: 26 · 2023: 39 · 2022: 32 · 2021: 43 · 2020: 47 · 2019: 40 · 2018: 47 · 2017: 53 · 2016: 63 · 2015: 57 · 2014: 55 · 2013: 65 · 2012: 76
FWCI: 1.84
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Advanced Drug Delivery Reviews (publishedVersion)
PubMed (publishedVersion)
Topics: Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords: blood-brain barrier, nanoparticle drug delivery, brain drug delivery, apolipoprotein E, glioblastoma, doxorubicin, neuropeptides, P-glycoprotein inhibition, tight junction modulation, transcytosis, central nervous system drugs
MeSH terms: Animals, Antineoplastic Agents, Blood-Brain Barrier, Brain, Brain Neoplasms, Capsules, Cells, Cultured, Doxorubicin, Drug Carriers, Endothelium, Vascular, Humans, Male, Polysorbates, Surface-Active Agents, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Nanoparticulate systems for brain delivery of drugs.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks